CUSIP 75886F107 · who reports it, how much, and how much it matters to them
50 of the 720 hedge fund managers we track reported shares of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) on Form 13F for 30 June 2026. Between them they reported USD 1.4bn. The largest position belongs to Two Sigma Investments, at USD 409m. The manager with the most riding on it is Bronte Capital Management Pty, where it is 10.9% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Two Sigma Investments35 funds on PPLI.com | USD 409m | 0.3% |
| 2 | Squarepoint Ops7 funds on PPLI.com | USD 124m | 0.1% |
| 3 | Millennium Management6 funds on PPLI.com | USD 103m | 0.0% |
| 4 | Voloridge Investment Management6 funds on PPLI.com | USD 102m | 0.4% |
| 5 | Bronte Capital Management Pty3 funds on PPLI.com | USD 101m | 10.9% |
| 6 | Renaissance Technologies13 funds on PPLI.com | USD 92m | 0.1% |
| 7 | Armistice Capital1 fund on PPLI.com | USD 56m | 0.7% |
| 8 | Adage Capital Management1 fund on PPLI.com | USD 52m | 0.1% |
| 9 | Grantham Mayo Van Otterloo & Co1 fund on PPLI.com | USD 46m | 0.1% |
| 10 | Citadel Advisors32 funds on PPLI.com | USD 36m | 0.0% |
| 11 | Bridgewater Associates45 funds on PPLI.com | USD 32m | 0.1% |
| 12 | CIBC Asset Management69 funds on PPLI.com | USD 26m | 0.1% |
| 13 | D. E. Shaw & Co.15 funds on PPLI.com | USD 24m | 0.0% |
| 14 | LMCG Investments2 funds on PPLI.com | USD 23m | 1.2% |
| 15 | Aquatic Capital Management3 funds on PPLI.com | USD 20m | 0.7% |
| 16 | IFM Investors Pty7 funds on PPLI.com | USD 15m | 0.1% |
| 17 | Marshall Wace LLP84 funds on PPLI.com | USD 14m | 0.0% |
| 18 | Walleye Capital8 funds on PPLI.com | USD 14m | 0.1% |
| 19 | LMR Partners2 funds on PPLI.com | USD 14m | 0.1% |
| 20 | Sio Capital Management4 funds on PPLI.com | USD 11m | 1.9% |
| 21 | Hudson Bay Capital Management8 funds on PPLI.com | USD 11m | 0.0% |
| 22 | Engineers Gate Manager1 fund on PPLI.com | USD 9.9m | 0.1% |
| 23 | Campbell & Company Investment Adviser8 funds on PPLI.com | USD 6.2m | 0.3% |
| 24 | Balyasny Asset Management25 funds on PPLI.com | USD 5.9m | 0.0% |
| 25 | Voleon Capital Management13 funds on PPLI.com | USD 5.3m | 0.1% |
| 26 | J. Goldman & Co.1 fund on PPLI.com | USD 4.3m | 0.1% |
| 27 | Arnhold3 funds on PPLI.com | USD 3.9m | 0.3% |
| 28 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 3m | 0.0% |
| 29 | Edgestream Partners5 funds on PPLI.com | USD 2.7m | 0.1% |
| 30 | Sarissa Capital Management6 funds on PPLI.com | USD 2.6m | 1.5% |
| 31 | Polymer Capital Management (HK)1 fund on PPLI.com | USD 2.3m | 0.1% |
| 32 | Boothbay Fund Management2 funds on PPLI.com | USD 2.1m | 0.0% |
| 33 | Verition Fund Management3 funds on PPLI.com | USD 2.1m | 0.0% |
| 34 | Dark Forest Capital Management2 funds on PPLI.com | USD 1.6m | 0.1% |
| 35 | Fora Capital1 fund on PPLI.com | USD 1.3m | 0.1% |
| 36 | Trust Asset Management4 funds on PPLI.com | USD 1.3m | 0.1% |
| 37 | Brevan Howard Capital Management39 funds on PPLI.com | USD 1.2m | 0.0% |
| 38 | Magnetar Financial93 funds on PPLI.com | USD 836,000 | 0.0% |
| 39 | Oxford Asset Management LLP2 funds on PPLI.com | USD 789,000 | 0.4% |
| 40 | Capstone Investment Advisors25 funds on PPLI.com | USD 773,000 | 0.0% |
| 41 | Kinneret Advisory7 funds on PPLI.com | USD 696,000 | 0.1% |
| 42 | Graham Capital Management18 funds on PPLI.com | USD 537,000 | 0.0% |
| 43 | Prelude Capital Management9 funds on PPLI.com | USD 464,000 | 0.0% |
| 44 | Gamco Asset Management1 fund on PPLI.com | USD 410,000 | 0.0% |
| 45 | BTG Pactual Asset Management US11 funds on PPLI.com | USD 369,000 | 0.0% |
| 46 | Seelaus Asset Management8 funds on PPLI.com | USD 312,000 | 0.2% |
| 47 | Landscape Capital Management4 funds on PPLI.com | USD 289,000 | 0.0% |
| 48 | MQS Management2 funds on PPLI.com | USD 257,000 | 0.3% |
| 49 | Alphadyne Asset Management1 fund on PPLI.com | USD 29,930 | 0.0% |
| 50 | Summit Global Investments1 fund on PPLI.com | USD 4,680 | 0.3% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Bronte Capital Management Pty | USD 101m | 10.9% |
| 2 | Sio Capital Management | USD 11m | 1.9% |
| 3 | Sarissa Capital Management | USD 2.6m | 1.5% |
| 4 | LMCG Investments | USD 23m | 1.2% |
| 5 | Aquatic Capital Management | USD 20m | 0.7% |
| 6 | Armistice Capital | USD 56m | 0.7% |
| 7 | Voloridge Investment Management | USD 102m | 0.4% |
| 8 | Oxford Asset Management LLP | USD 789,000 | 0.4% |
| 9 | Campbell & Company Investment Adviser | USD 6.2m | 0.3% |
| 10 | MQS Management | USD 257,000 | 0.3% |
Regeneron Pharmaceuticals, Inc. trades under the symbol REGN on the Nasdaq. Its CUSIP, the code used on Form 13F, is 75886F107.
50 of the 720 hedge fund managers PPLI.com tracks reported Regeneron Pharmaceuticals, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Two Sigma Investments (USD 409m), Squarepoint Ops (USD 124m), Millennium Management (USD 103m), Voloridge Investment Management (USD 102m) and Bronte Capital Management Pty (USD 101m).
50 managers in our coverage reported it, and between them they run 678 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Bronte Capital Management Pty, where the position was 10.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Regeneron Pharmaceuticals, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.